{"id":391515,"date":"2014-10-24T00:00:00","date_gmt":"2014-10-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforus0414-biopharma-oral-hif-ph-inhibitors-for-the-treatment-of-renal-anemia-in-ckd-non-dialysis-and-dialysis-how-will\/"},"modified":"2026-03-31T09:04:28","modified_gmt":"2026-03-31T09:04:28","slug":"pforus0414-biopharma-oral-hif-ph-inhibitors-for-the-treatment-of-renal-anemia-in-ckd-non-dialysis-and-dialysis-how-will","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforus0414-biopharma-oral-hif-ph-inhibitors-for-the-treatment-of-renal-anemia-in-ckd-non-dialysis-and-dialysis-how-will\/","title":{"rendered":"Oral HIF-PH Inhibitors for the Treatment of Renal Anemia in CKD Non-Dialysis and Dialysis: How Will U.S. Physicians and Payers Respond to This Novel Class? | Physician &#038; Payer Forum | US | 2014"},"content":{"rendered":"<p>Renal anemia and hyperphosphatemia, or elevated serum phosphorous, are two primary complications of chronic kidney disease (CKD) that are treated with erythropoiesis-stimulating agents (ESAs) and phosphate binders, respectively. The U.S. market for renal anemia drugs is poised to expand owing to the growing size of the CKD non-dialysis (CKD-ND) and dialysis patient populations, as well as the expected launches of novel therapies such as oral hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors to treat renal anemia (i.e., roxadustat, AKB-6548, GSK-1278863A, and molidustat). This report examines the dynamics that will limit or promote market access for emerging oral HIF-PH inhibitors in the pipeline as new drug launches are expected as early as 2018. We analyze physician prescribing of ESAs, future prescribing practices, the impact and uptake of oral HIF-PH inhibitors on current therapy use, and formulary decision making for current and emerging agents, among other topics.<\/p>\n","protected":false},"template":"","class_list":["post-391515","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-kidney-disease","biopharma-therapy-areas-renal-anemia","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391515","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391515\/revisions"}],"predecessor-version":[{"id":576996,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391515\/revisions\/576996"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}